Table 1.
Baseline characteristics for LT recipients and comparison of recipients with negative and positive SARS-CoV-2 S1/S2 IgG serology.
| Parameter | All LT recipients (n = 80) | Negative (n = 42) | Positive (n = 38) | p value |
|---|---|---|---|---|
| Age† (years) | 60.1 ± 12.8 | 63.22 ± 11.9 | 57.78 ± 11.9 | 0.04 |
| Sex, female (%)†† | 24 (30) | 14 (33.3) | 10 (26.3) | 0.63 |
| BMI† | 26.3 ± 4.6 | 25.83 ± 3.9 | 26.8 ± 5.6 | 0.33 |
| Months after first transplantation† | 76.6 ± 74.1 | 71.78 ± 71.2 | 89.2 ± 66.3 | 0.28 |
| Etiology of liver disease∗ | 0.18 | |||
| Viral | 39 (HCV 26, HBV 13) | 20 | 19 | |
| NASH/ALD | 16/3 | 13 | 6 | |
| AIH/PBC/PSC | 6/3/7 | 8 | 8 | |
| Other | 8∗∗ | 2 | 6 | |
| HCC, (%)†† | 26 (32.5) | 14 (33.3) | 12 (31.5) | 0.811 |
| HTN, (%)†† | 45 (56.2) | 25 (62.5) | 20 (51.2) | 0.36 |
| DM, (%)†† | 26 (32.5) | 15 (37.5) | 11 (28.2) | 0.47 |
| High dose steroids last 12 months | 16 (20) | 13 (30.9) | 3 (7.8) | 0.010 |
| Prednisone, (%)†† | 24 (30) | 16 (38) | 8 (21) | 0.086 |
| Daily dose (mg)††† | 5 (2.5-15) | |||
| CNIs, (%)†† | 75 (93.7) | 40 (95.2) | 35 (92.1) | 0.055 |
| Tacrolimus/cyclosporine | 65/10 | |||
| Drug level (ng/ml)††† | 5.9 (2.2-12.8)/72.5 (33-180) | |||
| Everolimus, (%)†† | 18 (22.5) | 9 (21.4) | 11 (28.9) | 0.612 |
| Drug level (ng/ml)††† | 3.45 (1.6-8) | |||
| Azathioprine (%) | 4 (5) | 1 (2.3) | 3 (7.8) | 0.358 |
| MMF, (%)†† | 40 (50) | 25 (59.5) | 15 (39.4) | 0.069 |
| Daily dose (mg)††† | 720 (250-2,000) | |||
| Hb† (g/dl) | 13.4 ± 1.6 | 13.11 ± 1.7 | 14.13 ± 1.5 | 0.04 |
| WBC† (103/μl) | 6.23 ± 2.1 | 5.83 ± 2.2 | 6.74 ± 1.6 | 0.054 |
| PMC† (103/μl) | 3.79 ± 1.5 | 3.63 ± 1.6 | 4.02 ± 1.4 | 0.307 |
| Lymphocyte† (103/μl) | 1.66 ± 0.8 | 1.59 ± 0.8 | 1.75 ± 0.7 | 0.427 |
| Platelet† (103/μl) | 156.6 ± 60.8 | 151.9 ± 60.2 | 168.3 ± 70.3 | 0.282 |
| eGFR† (ml/min) | 64.6 (±26.1) | 56.32 ± 22.4 | 75.17 ± 11.6 | 0.001 |
| Serum albumin† (g/L) | 40.8 ± 10.2 | 39.9 ± 11.0 | 41.8 ± 8.0 | 0.433 |
Date presented as: †Mean ± SD, ††number (percentage), †††Median (range). For all categorical variables, the Chi-Square statistic was used. Continuous variables were compared by using a t test if normally distributed or by Kruskal Wallis/Mann-Whitney test if non-normally distributed. p <0.05 was considered statistically significant for all analyses. ∗Two patients had multiple etiologies (HBV+HCV and HCV + congenital hepatic fibrosis). ∗∗ Other etiologies: Acute liver failure- 2, cryptogenic cirrhosis - 3, Wilson's disease- 1, secondary sclerosing cholangitis- 1 and congenital hepatic fibrosis - 1.
AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; CNIs, calcineurin inhibitors; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma; HTN, hypertension; MMF, mycophenolate mofetil; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PMC, polymorphonuclear cell; PSC, primary sclerosing cholangitis, WBC, white blood cell.